Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.95), $0.17 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $2.06 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.